Australia's largest stock trading and investment forum Australia's #1 stock forum

TLX

Click for more information

0.15%

$20.48 telix pharmaceuticals limited

As far as i can tell its not either or.Cu6 will have a large...

First 1403 Last

Share
Profile

Follow
flotsam222

5,001 Posts.

339

01/09/24

21:04

Post #: 75478273
Share
Originally posted by nathan1984: ↑

For those that are interested in a comparison in commercial plausibility and science RE diagnostic TLX vs CU6-

Developing ⁶⁴Cu (Copper-64) for theranostic radiopharmaceutical applications presents unique challenges and risks compared to ⁶⁸Ga (Gallium-68). Here are some key considerations:
1. Production and Availability
⁶⁴Cu:
Production Method: ⁶⁴Cu is typically produced via cyclotron, requiring a proton beam to irradiate a nickel-64 target. The production process is more complex and requires specialized equipment.
Availability: The infrastructure needed for cyclotron production of ⁶⁴Cu is less widespread, leading to limited availability and higher costs.
⁶⁸Ga:
Production Method: ⁶⁸Ga is commonly sourced from a germanium-68/⁶⁸Ga generator, making it more widely accessible and convenient, especially in clinical settings without cyclotron facilities.
Availability: The ease of production and broader distribution networks make ⁶⁸Ga more readily available.
2. Half-Life
⁶⁴Cu:
Half-Life: ⁶⁴Cu has a half-life of approximately 12.7 hours, which provides sufficient time for complex synthesis, quality control, and distribution. However, this also means a longer duration of radiation exposure to the patient.
⁶⁸Ga:
Half-Life: ⁶⁸Ga has a shorter half-life of about 68 minutes, necessitating rapid synthesis and administration but reducing long-term radiation exposure to patients.
3. Decay Properties
⁶⁴Cu:
Decay Modes: ⁶⁴Cu decays by both positron emission (18%) and beta emission (39%), allowing it to be used for both diagnostic (PET imaging) and therapeutic purposes. However, the beta particles also contribute to higher radiation doses, potentially increasing toxicity.
⁶⁸Ga:
Decay Mode: ⁶⁸Ga primarily undergoes positron emission, which is ideal for PET imaging, with minimal additional radiation, making it more focused on diagnostic applications.
4. Radiolabeling Chemistry
⁶⁴Cu:
Complexity: The radiolabeling of ⁶⁴Cu often requires chelators like DOTA or NOTA, which can be more challenging in terms of stability and kinetics compared to ⁶⁸Ga.
⁶⁸Ga:
Simplicity: ⁶⁸Ga radiolabeling is typically faster and simpler, with well-established chelators (e.g., DOTA, NOTA) and protocols. This makes it more user-friendly in clinical and research settings.
5. Dosimetry and Safety
⁶⁴Cu:
Higher Radiation Dose: The mixed decay modes of ⁶⁴Cu result in a higher radiation dose to patients, which may pose increased risks, especially in therapeutic applications.
⁶⁸Ga:
Lower Radiation Dose: The pure positron emission of ⁶⁸Ga results in a lower overall radiation dose, enhancing its safety profile for diagnostic imaging.
6. Regulatory and Economic Considerations
⁶⁴Cu:
Regulatory Complexity: The dual nature of ⁶⁴Cu as both a diagnostic and therapeutic agent may lead to more complex regulatory pathways.
Cost: The higher cost of production and limited availability may also present economic challenges for widespread clinical adoption.
⁶⁸Ga:
Regulatory Simplicity: With a more established track record and simpler regulatory pathways, ⁶⁸Ga faces fewer barriers in clinical deployment.
Summary
While ⁶⁴Cu offers the advantage of being both a diagnostic and therapeutic agent, its development faces challenges in production complexity, higher radiation dose, and economic and regulatory hurdles. In contrast, ⁶⁸Ga is more widely available, easier to use, and safer for purely diagnostic purposes, making it a more convenient choice in many clinical settings.

Expand

As far as i can tell its not either or.

Cu6 will have a large market for their Cu64 imaging agent by the looks.

Likely more for metastatic and recurrence and monitoring after treatment. Its able to pick out much smaller lesions.

The comment from a clinician in an interview was that he would use it in half of his patients.

I still believe the majority of initial diagnoses will be through an illucix or pylarify scan.

Too early to tell with their therapy but as I said before there's a good chance kidney damage is an issue.
TLX Price at posting: $18.61 Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 173 more messages in this thread...

First 1403 Last

Add TLX (ASX) to my watchlist

(20min delay)
Last $20.48		Change 0.030(0.15%)		Mkt cap ! $6.854B

Open	High	Low	Value	Volume
$20.35	$20.83	$20.30	$10.68M	520.3K

Buyers (Bids)

No.	Vol.	Price($)
1	1586	$20.48

Sellers (Offers)

Price($)	Vol.	No.
$20.58	898	2

View Market Depth

No.	Vol.	Price($)
1	387	20.410
1	196	20.400
1	2	20.300
1	1000	20.290
1	300	20.160

Price($)	Vol.	No.
20.700	4500	1
20.750	500	1
20.800	1792	2
20.880	1784	2
20.890	3000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

TLX (ASX) Chart